Global BREO Ellipta Drugs Market Report and Forecast 2023-2031
Market Report I 2023-03-22 I 147 Pages I EMR Inc.
Global BREO Ellipta Drugs Market Report and Forecast 2023-2031
Global BREO Ellipta Drugs Market Outlook
The global BREO ellipta drugs market is driven by the growing chronic obstructive pulmonary disease drugs market, which is likely to grow at a rate of 4.50% during the forecast period of 2023-2031. The prevalence of these respiratory disease is expected to rise significantly over the coming years due to rising pollution levels, along with other factors.
Introduction to the BREO Ellipta Drugs Market
BREO Ellipta is a combination drug that contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist. The drug is used to treat asthma and chronic obstructive pulmonary disease (COPD) by reducing inflammation in the airways and relaxing the muscles around the airways to improve breathing. The increasing prevalence of respiratory disorders, such as asthma and COPD, is driving the demand for BREO Ellipta drugs. Factors such as aging population, increasing air pollution, and rising awareness about the importance of effective treatment for respiratory disorders are also expected to drive market growth.
Advancements in technology and drug delivery systems have played a significant role in the growth of the BREO Ellipta drugs market. The development of inhalers with improved drug delivery and reduced side effects has expanded the reach of BREO Ellipta drugs and helped to meet the growing demand for these medications.
The BREO Ellipta drugs market is expected to continue to grow in the coming years, as awareness of the importance of effective treatment for respiratory disorders increases, and new treatment options and technologies are developed to meet the needs of patients with asthma and COPD. However, there are still significant barriers to accessing BREO Ellipta drugs, particularly in low- and middle-income countries, where access to healthcare services is often limited. Efforts are underway to address these barriers and improve access to BREO Ellipta drugs globally.
Global BREO Ellipta Drugs Market- Applications
BREO Ellipta drugs market has significant applications in the treatment and management of respiratory disorders, primarily chronic obstructive pulmonary disease (COPD) and asthma. The drug's ability to reduce inflammation and relax the muscles in the airways has made it a popular choice for patients and healthcare providers worldwide.
As the prevalence of these respiratory disorders continues to rise, driven by factors such as aging population, urbanization, and increasing air pollution, the demand for effective treatment options like BREO Ellipta is expected to grow. This growth will likely be supported by technological advancements, improved drug delivery systems, and increased awareness of respiratory disorders and their treatments. However, challenges remain in terms of accessibility, especially in low- and middle-income countries, where healthcare infrastructure and resources may be limited.
Overall, the global BREO Ellipta drugs market is poised for continued growth in the coming years, driven by its essential applications in the management of COPD and asthma and the increasing need for innovative and effective treatments for these respiratory conditions.
BREO Ellipta Drugs Market Segmentations
The market can be segmented based on indication type, mode of administration, distribution channel, and region:
Market Breakup by Indication Type
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Chronic Bronchitis
- Asthma
- Others
Market Breakup by Mode of Administration
- Dry Powder Inhaler
- Respimat Soft Mist Inhaler
- Pressurized Metered Dose Inhaler
- Nebulizers
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
BREO Ellipta Drugs Market Analysis
The global BREO Ellipta drugs market is expected to experience significant growth over the forecast period, driven by factors such as the increasing prevalence of asthma and COPD, and the rising demand for effective and innovative treatments for these respiratory disorders.
The North America region is currently the largest market for BREO Ellipta drugs, dominating the market with a significant share. The region's large market share is driven by factors such as a high prevalence of respiratory disorders, well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of BREO Ellipta drugs is further driving the growth of the market in North America. Europe is also a significant market for BREO Ellipta drugs, with countries such as Germany, France, and the UK leading the way. The region's market growth is driven by factors such as a large population base, increasing prevalence of respiratory disorders, and the availability of BREO Ellipta drugs through various distribution channels.
The Asia Pacific region is another region that is experiencing significant growth in the BREO Ellipta drugs market. The region's market growth is driven by factors such as a large population base, increasing awareness about respiratory disorders, and the growing adoption of BREO Ellipta drugs. In addition, government initiatives to address respiratory disorders are helping to drive the growth of the market in the region.
Key Suppliers in the Global BREO Ellipta Drugs Market
The report provides a detailed analysis of the key suppliers involved in the BREO Ellipta drugs market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
- GSK plc
- Akros Pharma Inc
- Sun Pharmaceutical Industries Ltd
- Gilead Sciences, Inc.
- Abbott
- Genosco Inc.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Breo Ellipta Drugs Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Breo Ellipta Drugs Market
6.1 Global Breo Ellipta Drugs Market Overview
6.2 Global Breo Ellipta Drugs Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Breo Ellipta Drugs Market Historical Value (2016-2022)
6.2.1.2 Global Breo Ellipta Drugs Market Forecast Value (2023-2031)
6.3 Global Breo Ellipta Drugs Market by Indication Type
6.3.1 Market Overview
6.3.1.1 Chronic Obstructive Pulmonary Disease (COPD)
6.3.1.2 Cystic Fibrosis
6.3.1.3 Chronic Bronchitis
6.3.1.4 Asthma
6.3.1.5 Others
6.4 Global Breo Ellipta Drugs Market by Mode of Administration
6.4.1 Market Overview
6.4.1.1 Dry Powder Inhaler
6.4.1.2 Respimat Soft Mist Inhaler
6.4.1.3 Pressurized Metered Dose Inhaler
6.4.1.4 Nebulizers
6.4.1.5 Others
6.5 Global Breo Ellipta Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.1.1 Hospital Based Pharmacies
6.5.1.2 Online Pharmacies
6.5.1.3 Retail Pharmacies
6.6 Global Breo Ellipta Drugs Market by Region
6.6.1 Market Overview
6.6.1.1 North America
6.6.1.1.1 Historical Trend (2016-2022)
6.6.1.1.2 Forecast Trend (2023-2031)
6.6.1.2 Europe
6.6.1.2.1 Historical Trend (2016-2022)
6.6.1.2.2 Forecast Trend (2023-2031)
6.6.1.3 Asia Pacific
6.6.1.3.1 Historical Trend (2016-2022)
6.6.1.3.2 Forecast Trend (2023-2031)
6.6.1.4 Latin America
6.6.1.4.1 Historical Trend (2016-2022)
6.6.1.4.2 Forecast Trend (2023-2031)
6.6.1.5 Middle East and Africa
6.6.1.5.1 Historical Trend (2016-2022)
6.6.1.5.2 Forecast Trend (2023-2031)
7 North America Breo Ellipta Drugs Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2 Canada
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Breo Ellipta Drugs Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2 Germany
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 France
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 Italy
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Breo Ellipta Drugs Market
9.1 China
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 Japan
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 India
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 ASEAN
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 Australia
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Breo Ellipta Drugs Market
10.1 Brazil
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2 Argentina
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Mexico
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Breo Ellipta Drugs Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Nigeria
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges & Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Breo Ellipta Drugs Market Dynamics
14.1 Market Drivers and Constraints
14.2 Drug Adoption Parameters
14.3 SWOT Analysis
14.4 Porter Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Industry Events, Initiatives, and Trends
14.8 Value Chain Analysis
15 Supplier Landscape
15.1 GSK plc
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Akros Pharma Inc
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Sun Pharmaceutical Industries Ltd
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Gilead Sciences, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Abbott
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Genosco Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
16 Recommendations and Discussion
17 Pricing Models and Strategies (Additional Insight)
17.1 Cost Model
17.1.1 Manufacturing Cost Analysis
17.1.2 Procurement Cost Analysis
17.2 Pricing Strategies
17.2.1 Competitor Pricing Analysis
17.2.2 Key Assessment of Product Attributes
17.2.3 Pricing Benchmark
18 Global Breo Ellipta Drugs Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.